Replies to post #120601 on Biotech Values

[DewDiligence]

Respectfully, I think you have this backwards. The lack of a clinical benefit in the AIM-HIGH study reduces the likelihood that AMRN’s outcomes study for AMR-101 will turn out positive, and this lessens the value of the AMR-101 program to potential suitors.